Hyperfine Enrolls First Patient in Swoop Portable MRI Contrast Agent Feasibility Study
Hyperfine has enrolled the first patient in a prospective study evaluating contrast-enhanced ultra-low-field portable MRI using its Swoop System. The study, conducted in Guilford, Conn., aims to assess feasibility and visualization benefits of contrast agents for expanded intended use.
Related News
CBRS
Nvidia beats Q1 EPS and revenue estimates, forecasts $89.1–$92.8B Q2 sales
CBRS•
TSLA
SpaceX $1.25 Trillion IPO Could Lift Musk’s Wealth Above $1 Trillion
TSLA•
NVDA
Nvidia Raises Dividend to $0.25, Launches $80B Buyback after $91B Forecast
NVDA•
EQNR
Equinor Sells 19% Ringvei Vest Stakes, Increases Wisting to 42.5% for $23M
EQNR•
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
Sources
BB